However, except for ALK + anaplastic large-cell lymphoma (ALCL), most peripheral T-cell lymphomas (PTCLs) are highly malignant and have an aggressive disease course and poor clinical outcomes, with poor remission rates and frequent relapse after first-line treatment [6]. The gene discussed is ALK; the disease is peripheral T-cell lymphoma, not otherwise specified.